Linked Clusters of SARS-CoV-2 Variant B.1.351 - Maryland, January-February 2021.
Kenneth A. Feder,Marcia Pearlowitz,Alexandra Goode,Monique Duwell,Thelonious W. Williams,Ping An Chen-Carrington,Ami Patel,Catherine Dominguez,Eric N. Keller,Liore Klein,Alessandra Rivera-Colon,Heba H. Mostafa,C. Paul Morris,Neil Patel,Anna M. Schauer,Robert Myers,David Blythe,Katherine A. Feldman +17 more
Reads0
Chats0
TLDR
The first identified linked clusters of B.1.351 infections in the United States with no apparent link to international travel highlight the importance of expanding the scope and volume of genetic surveillance programs to identify variants, completing contact investigations for SARS-CoV-2 infections, and using universal prevention strategies, including vaccination, masking, and physical distancing as mentioned in this paper.Abstract:
In late January 2021, a clinical laboratory notified the Maryland Department of Health (MDH) that the SARS-CoV-2 variant of concern B.1.351 had been identified in a specimen collected from a Maryland resident with COVID-19 (1). The SARS-CoV-2 B.1.351 lineage was first identified in South Africa (2) and might be neutralized less effectively by antibodies produced after vaccination or natural infection with other strains (3-6). To limit SARS-CoV-2 chains of transmission associated with this index patient, MDH used contact tracing to identify the source of infection and any linked infections among other persons. The investigation identified two linked clusters of SARS-CoV-2 infection that included 17 patients. Three additional specimens from these clusters were sequenced; all three had the B.1.351 variant and all sequences were closely related to the sequence from the index patient's specimen. Among the 17 patients identified, none reported recent international travel or contact with international travelers. Two patients, including the index patient, had received the first of a 2-dose COVID-19 vaccination series in the 2 weeks before their likely exposure; one additional patient had a confirmed SARS-CoV-2 infection 5 months before exposure. Two patients were hospitalized with COVID-19, and one died. These first identified linked clusters of B.1.351 infections in the United States with no apparent link to international travel highlight the importance of expanding the scope and volume of genetic surveillance programs to identify variants, completing contact investigations for SARS-CoV-2 infections, and using universal prevention strategies, including vaccination, masking, and physical distancing, to control the spread of variants of concern.read more
Citations
More filters
Posted ContentDOI
Infection with the SARS-CoV-2 Delta Variant is Associated with Higher Infectious Virus Loads Compared to the Alpha Variant in both Unvaccinated and Vaccinated Individuals
Chun Huai Luo,C. Paul Morris,C. Paul Morris,Jaiprasath Sachithanandham,Adannaya Amadi,David C. Gaston,Maggie Li,Nicholas J Swanson,Matthew D. Schwartz,Eili Y. Klein,Eili Y. Klein,Andrew Pekosz,Heba H. Mostafa +12 more
TL;DR: In this paper, the prevalence of SARS-CoV-2 lineages circulating in the National Capital Region between January and July 2021 was analyzed using whole genome sequencing (WG sequenceto-sequencing) of 2,785 clinical isolates.
Journal ArticleDOI
Present variants of concern and variants of interest of severe acute respiratory syndrome coronavirus 2: Their significant mutations in S-glycoprotein, infectivity, re-infectivity, immune escape and vaccines activity
TL;DR: In this paper, the authors have discussed the appearance of significant alarming SARS-CoV-2 variants in the entire world and discussed the properties of the substantial variant of concern (VOC) variants such as B.1.525 and B.617.
Journal ArticleDOI
Structural and functional insights into the spike protein mutations of emerging SARS-CoV-2 variants.
TL;DR: In this paper, the authors focused on the current circulating variants of SARS-CoV-2 and the structure-function analysis of key S protein mutations linked with increased affinity, higher infectivity, enhanced transmission rates, and immune escape against this infection.
Journal ArticleDOI
An Update on SARS-CoV-2 Diversity in the United States National Capital Region: Evolution of Novel and Variants of Concern.
C. Paul Morris,C. Paul Morris,Chun Huai Luo,Adannaya Amadi,Matthew D. Schwartz,Nicholas Gallagher,Stuart C. Ray,Andrew Pekosz,Heba H. Mostafa +8 more
TL;DR: In this paper, a large-scale whole-genome sequencing was performed between November 2020 and end of March 2021 to provide a phylodynamic analysis of circulating variants over time, and compared the viral genomic features of March 2020 and March 2021.
Journal ArticleDOI
Biological Properties of SARS-CoV-2 Variants: Epidemiological Impact and Clinical Consequences
Reem Hoteit,Hadi M. Yassine +1 more
TL;DR: Key information is examined and provided on SARS-CoV-2 VOCs, including their transmissibility, infectivity rate, disease severity, affinity for angiotensin-converting enzyme 2 (ACE2) receptors, viral load, reproduction number, vaccination effectiveness, and vaccine breakthrough.
References
More filters
Posted ContentDOI
Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa
Houriiyah Tegally,Eduan Wilkinson,Marta Giovanetti,Marta Giovanetti,Arash Iranzadeh,Vagner Fonseca,Vagner Fonseca,Jennifer Giandhari,Deelan Doolabh,Sureshnee Pillay,Emmanuel James San,Nokukhanya Msomi,Koleka Mlisana,Koleka Mlisana,Anne von Gottberg,Anne von Gottberg,Sibongile Walaza,Sibongile Walaza,Mushal Allam,Arshad Ismail,Thabo Mohale,Allison J. Glass,Susan Engelbrecht,Gert U. van Zyl,Wolfgang Preiser,Francesco Petruccione,Alex Sigal,Alex Sigal,Diana Hardie,Gert Marais,Marvin Hsiao,Stephen N.J. Korsman,Mary-Ann Davies,Lynn Tyers,Innocent Mudau,Denis York,Caroline Maslo,Dominique Goedhals,Shareef Abrahams,Oluwakemi Laguda-Akingba,Oluwakemi Laguda-Akingba,Arghavan Alisoltani-Dehkordi,Arghavan Alisoltani-Dehkordi,Adam Godzik,Constantinos Kurt Wibmer,B.T. Sewell,José Lourenço,Luiz Carlos Junior Alcantara,Luiz Carlos Junior Alcantara,Sergei L Kosakovsky Pond,Steven Weaver,Darren P. Martin,Richard J Lessells,Richard J Lessells,Jinal N. Bhiman,Jinal N. Bhiman,Carolyn Williamson,Carolyn Williamson,Tulio de Oliveira,Tulio de Oliveira,Tulio de Oliveira +60 more
TL;DR: In this paper, the authors describe a new SARS-CoV-2 lineage (501Y.V2) characterised by eight lineage-defining mutations in the spike protein, including three at important residues in the receptor-binding domain (K417N, E484K and N501Y).
Posted ContentDOI
mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants
Kai Wu,Anne P. Werner,Juan I. Moliva,Matthew A. Koch,Angela Choi,Guillaume Stewart-Jones,Hamilton Bennett,Seyhan Boyoglu-Barnum,Wei Shi,Barney S. Graham,Andrea Carfi,Kizzmekia S. Corbett,Robert A. Seder,Darin K. Edwards +13 more
TL;DR: In this paper, the authors assessed the neutralizing capacity of sera from human subjects or non-human primates (NHPs) that received mRNA-1273 vaccination, using two orthogonal VSV and lentivirus PsVN assays expressing spike variants of 20E (EU1), 20A.7, and B.1.351.
Posted ContentDOI
Safety and efficacy of the ChAdOx1 nCoV-19 (AZD1222) Covid-19 vaccine against the B.1.351 variant in South Africa
Shabir A. Madhi,Shabir A. Madhi,Baillie,Baillie,Clare L. Cutland,Merryn Voysey,Anthonet Koen,Anthonet Koen,Lee Fairlie,S D Padayachee,Keertan Dheda,Shaun Barnabas,Q E Bhorat,Carmen Briner,Gaurav Kwatra,Gaurav Kwatra,Khatija Ahmed,Parvinder K. Aley,Bhikha S,Bhikha S,Jinal N. Bhiman,Jinal N. Bhiman,As’ad E. Bhorat,Plessis Jd,Plessis Jd,Aliasgar Esmail,M M Groenewald,E Horne,Shi-Hsia Hwa,Aylin Oommen Jose,Teresa Lambe,Laubscher M,M Malahleha,Masebole Masenya,Mduduzi Masilela,McKenzie S,K Molapo,A Moultrie,Oelofse S,F Patel,Sureshnee Pillay,S Rhead,Hylton Errol Rodel,L Rossouw,C Taoushanis,Houriiyah Tegally,Asha Thombrayil,Eck Sv,Constantinos Kurt Wibmer,Constantinos Kurt Wibmer,Nicholas M. Durham,Elizabeth J. Kelly,Tonya Villafana,Sarah C. Gilbert,Andrew J. Pollard,de Oliveira T,Penelope L. Moore,Penelope L. Moore,Alex Sigal,Alane Izu,Alane Izu +60 more
TL;DR: A two-dose regimen of ChAdOx1-nCoV19 did not show protection against mild-moderate Covid-19 due to B. 1.1.351 variant, however, VE against severe Covd-19 is undetermined.
Related Papers (5)
Trajectory of Growth of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants in Houston, Texas, January through May 2021, Based on 12,476 Genome Sequences.
Randall J. Olsen,Randall J. Olsen,Paul A. Christensen,S. Wesley Long,S. Wesley Long,Sishir Subedi,Parsa Hodjat,Robert Olson,Robert Olson,Marcus Nguyen,Marcus Nguyen,James J. Davis,James J. Davis,Prasanti Yerramilli,Matthew Ojeda Saavedra,Layne Pruitt,Kristina Reppond,Madison N. Shyer,Jessica Cambric,Ryan Gadd,Rashi M. Thakur,Akanksha Batajoo,Ilya J. Finkelstein,Jimmy Gollihar,Jimmy Gollihar,James M. Musser,James M. Musser +26 more